Beijing Gene+ Raises $38 Million for Cancer Diagnostics

Beijing Gene+, a company using next-gen sequencing for oncology diagnostics, raised $38 million in a Series B round. Gene+ has developed NGS and genetic big data platforms to support four major businesses: clinical testing, medical equipment, scientific-technological cooperation and early tumor screening. In 2019, the company announced its domestically produced sequencers, kits and supporting software were all certified for use in China . Its first funding was led by China sequencing company BGI. More details.... Share this with colleagues: // //